Clinical Trial Update: Veliflapon (DG-031)to Prevent Heart Attacks or Stroke in Patients With a History of Heart Attack or Unstable Angina [Phase 3]

View source ↗

Summary

Phase 3 trial of Veliflapon (DG-031) to prevent heart attacks or strokes in patients with a history of acute coronary events has been suspended.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Syndrome

Drugs mentioned

• Veliflapon

Snippet

Sponsor: deCODE genetics | Conditions: Acute Coronary Syndrome | Phase 3 | Status: SUSPENDED